Abdera raises $142M to engineer oncology radiopharmaceuticals

The biotech is going after small-cell lung cancer and other solid tumors with its proprietary radiopharma target design platform
April 20, 2023

Abdera Therapeutics, a Canada-based biotech developing oncology therapies, announced this week that it has raised $142 million in combined Series A and B financing to develop radiopharmaceuticals for cancers.

The biotech’s proprietary Radio Optimized Vector Engineering (ROVEr™) platform allows for the design of antibody-based radiopharmaceuticals with antigen-binding domains that optimize the antibodies' pharmacokinetics for delivering therapeutic isotopes effectively. 

Its lead program — which has an expected investigational new drug (IND) application submission in 2024 — targets the delta-like ligand 3 (DLL3) protein for the treatment of small cell lung cancer and other sold tumors. 

Abdera’s president and CEO, Lori Lyons-Williams has over 20 years of industry experience both in multinational pharma companies and emerging biotech companies. She served as the chief commercial officer of Dremira, a biopharma company focused on immunology and medical dermatology which was later acquired by Eli Lilly for $1.1 billion. 

Abdera's series A funding round was spearheaded by Versant Ventures and Amplitude Ventures, along with contributions from Northview Ventures and Abdera's founding partners, AbCellera and adMare BioInnovations. The Series B funding round was led by venBio Partners with support from new investors like Viking Global Investors, and Qiming Venture Partners USA.

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates